BACKGROUND AND AIMS: Spastic esophageal disorders (SEDs) include spastic achalasia (type III), diffuse esophageal spasm (DES), and nutcracker/jackhammer esophagus (JH). Per-oral endoscopic myotomy (POEM) has demonstrated efficacy and safety in the treatment of achalasia. Recently, POEM has been indicated for the treatment of SEDs. We conducted a systematic review and meta-analysis to determine the clinical success and safety of POEM in SEDs. METHODS: We searched several databases from 01/01/2007 to 01/10/2016 to identify studies (with five or more patients) on POEM for the treatment of SEDs. Weighted pooled rates (WPRs) for clinical success and adverse events (AEs) were calculated for all SEDs. Clinical success was defined as Eckardt scores of ≤3 and/or improvement in severity of dysphagia based on achalasia disease-specific health-related quality of life questionnaire. The WPRs for clinical success and AEs were analyzed using fixed- or random-effects model based on heterogeneity. The proportionate difference in clinical success and post-procedure adverse event rates among individual types of SEDs was also calculated. RESULTS: A total of eight observational studies with 179 patients were included in the final analysis. Two studies were of good quality and six were of fair quality based on the National Institutes of Health quality assessment tool. The WPR with 95% confidence interval (CI) for cumulative clinical success of POEM in all SEDs was 87% (78, 93%), I 2 = 37%. The total number of patients for individual disorders, i.e., type III achalasia, JH, and DES, was 116, 37, and 18, respectively. The WPRs for clinical success of POEM for type III achalasia, DES, and JH were 92, 88, and 72%, respectively. Proportion difference of WPR for clinical success was significantly higher for type III achalasia in comparison with JH (20%, P = 0.01). The WPR with 95% CI for AEs of POEM in all SEDs was 14% (9, 20%), I 2 = 0%. The WPRs for post-procedure adverse events for type III achalasia, DES, and JH were 11, 14, and 16%, respectively. There was no difference in safety of POEM among individual SEDs. CONCLUSION: POEM is an effective and safe therapeutic modality for the treatment of spastic esophageal disorders.
BACKGROUND AND AIMS: Spastic esophageal disorders (SEDs) include spastic achalasia (type III), diffuse esophageal spasm (DES), and nutcracker/jackhammer esophagus (JH). Per-oral endoscopic myotomy (POEM) has demonstrated efficacy and safety in the treatment of achalasia. Recently, POEM has been indicated for the treatment of SEDs. We conducted a systematic review and meta-analysis to determine the clinical success and safety of POEM in SEDs. METHODS: We searched several databases from 01/01/2007 to 01/10/2016 to identify studies (with five or more patients) on POEM for the treatment of SEDs. Weighted pooled rates (WPRs) for clinical success and adverse events (AEs) were calculated for all SEDs. Clinical success was defined as Eckardt scores of ≤3 and/or improvement in severity of dysphagia based on achalasia disease-specific health-related quality of life questionnaire. The WPRs for clinical success and AEs were analyzed using fixed- or random-effects model based on heterogeneity. The proportionate difference in clinical success and post-procedure adverse event rates among individual types of SEDs was also calculated. RESULTS: A total of eight observational studies with 179 patients were included in the final analysis. Two studies were of good quality and six were of fair quality based on the National Institutes of Health quality assessment tool. The WPR with 95% confidence interval (CI) for cumulative clinical success of POEM in all SEDs was 87% (78, 93%), I 2 = 37%. The total number of patients for individual disorders, i.e., type III achalasia, JH, and DES, was 116, 37, and 18, respectively. The WPRs for clinical success of POEM for type III achalasia, DES, and JH were 92, 88, and 72%, respectively. Proportion difference of WPR for clinical success was significantly higher for type III achalasia in comparison with JH (20%, P = 0.01). The WPR with 95% CI for AEs of POEM in all SEDs was 14% (9, 20%), I 2 = 0%. The WPRs for post-procedure adverse events for type III achalasia, DES, and JH were 11, 14, and 16%, respectively. There was no difference in safety of POEM among individual SEDs. CONCLUSION: POEM is an effective and safe therapeutic modality for the treatment of spastic esophageal disorders.
Authors: Yuki B Werner; Guido Costamagna; Lee L Swanström; Daniel von Renteln; Pietro Familiari; Ahmed M Sharata; Tania Noder; Guido Schachschal; Jan F Kersten; Thomas Rösch Journal: Gut Date: 2015-04-30 Impact factor: 23.059
Authors: Mouen A Khashab; Ahmed A Messallam; Manabu Onimaru; Ezra N Teitelbaum; Michael B Ujiki; Matthew E Gitelis; Rani J Modayil; Eric S Hungness; Stavros N Stavropoulos; Mohamad H El Zein; Hironari Shiwaku; Rastislav Kunda; Alessandro Repici; Hitomi Minami; Philip W Chiu; Jeffrey Ponsky; Vivek Kumbhari; Payal Saxena; Amit P Maydeo; Haruhiro Inoue Journal: Gastrointest Endosc Date: 2015-01-26 Impact factor: 9.427
Authors: Ahmed M Sharata; Christy M Dunst; Radu Pescarus; Eran Shlomovitz; Aaron J T Wille; Kevin M Reavis; Lee L Swanström Journal: J Gastrointest Surg Date: 2014-09-03 Impact factor: 3.452
Authors: Ezra N Teitelbaum; Nathaniel J Soper; Byron F Santos; Fahd O Arafat; John E Pandolfino; Peter J Kahrilas; Ikuo Hirano; Eric S Hungness Journal: Surg Endosc Date: 2014-06-18 Impact factor: 4.584
Authors: John E Pandolfino; Monika A Kwiatek; Thomas Nealis; William Bulsiewicz; Jennifer Post; Peter J Kahrilas Journal: Gastroenterology Date: 2008-07-22 Impact factor: 22.682
Authors: Vivek Kumbhari; Alan H Tieu; Manabu Onimaru; Mohammad H El Zein; Ezra N Teitelbaum; Michael B Ujiki; Matthew E Gitelis; Rani J Modayil; Eric S Hungness; Stavros N Stavropoulos; Hiro Shiwaku; Rastislav Kunda; Philip Chiu; Payal Saxena; Ahmed A Messallam; Haruhiro Inoue; Mouen A Khashab Journal: Endosc Int Open Date: 2015-04-13
Authors: Peter J Kahrilas; Albert J Bredenoord; Dustin A Carlson; John E Pandolfino Journal: Clin Gastroenterol Hepatol Date: 2018-04-24 Impact factor: 11.382
Authors: Peter J Kahrilas; Albert J Bredenoord; Mark Fox; C Prakash Gyawali; Sabine Roman; André J P M Smout; John E Pandolfino Journal: Nat Rev Gastroenterol Hepatol Date: 2017-09-27 Impact factor: 46.802
Authors: Ishita Dhawan; Brendon O'Connell; Amit Patel; Ron Schey; Henry P Parkman; Frank Friedenberg Journal: Dig Dis Sci Date: 2018-12 Impact factor: 3.199
Authors: Filippo Filicori; Christy M Dunst; Ahmed Sharata; Walaa F Abdelmoaty; Ahmed M Zihni; Kevin M Reavis; Steven R Demeester; Lee L Swanström Journal: Surg Endosc Date: 2018-09-19 Impact factor: 4.584
Authors: Jan Friso Nast; Christoph Berliner; Thomas Rösch; Daniel von Renteln; Tania Noder; Guido Schachschal; Stefan Groth; Harald Ittrich; Jan F Kersten; Gerhard Adam; Yuki B Werner Journal: Surg Endosc Date: 2018-03-15 Impact factor: 4.584